Q4 2025 · 13F-HR
Ishara Investments LPholdings as filed
Filed 2026-02-17 · accession 0002111609-26-000001
$87.5M
Reported value
38
Positions
2025-12-31
Period end
The Brief · Ishara Investments LP · Q4 2025
AI · grounded in 13F
Ishara Investments LP established a new position in PRAX valued at $11.79M. The fund also initiated new stakes in XERS for $6.28M and BMRN for $5.94M. Additional new positions include AM6 at $5.13M and ACAD at $4.27M. The fund ended the period with 38 positions and total AUM of $87.46M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $11.8M | 13.5% | 40,000 | Common | SOLE |
| 98422E103 | XERS | XERIS BIOPHARMA HOLDINGS INC | $6.3M | 7.18% | 800,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $5.9M | 6.80% | 100,000 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $5.1M | 5.86% | 360,000 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $4.3M | 4.89% | 160,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $3.8M | 4.31% | 750,000 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $3.6M | 4.10% | 400,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $2.8M | 3.15% | 36,000 | Common | SOLE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $2.7M | 3.13% | 36,000 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $2.7M | 3.06% | 5,500 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $2.3M | 2.68% | 300,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $2.3M | 2.64% | 50,000 | Common | SOLE |
| 372303206 | GMAB | GENMAB A/S | $2.2M | 2.47% | 70,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $2.1M | 2.40% | 100,000 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $2.1M | 2.38% | 270,000 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $2.0M | 2.25% | 24,000 | Common | SOLE |
| 037598109 | APOG | APOGEE ENTERPRISES INC | $1.9M | 2.16% | 25,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $1.8M | 2.04% | 1,320,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $1.7M | 1.99% | 10,000 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $1.5M | 1.75% | 44,000 | CALL | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $1.5M | 1.67% | 240,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $1.4M | 1.65% | 58,000 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $1.4M | 1.58% | 50,000 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $1.3M | 1.50% | 160,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $1.3M | 1.44% | 50,000 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $1.2M | 1.32% | 70,000 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $1.1M | 1.31% | 50,000 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $1.1M | 1.22% | 5,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $1.1M | 1.20% | 30,000 | Common | SOLE |
| 528872302 | LXRX | LEXICON PHARMACEUTICALS INC | $1.0M | 1.16% | 880,000 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $993,520 | 1.14% | 88,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $989,040 | 1.13% | 24,000 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $845,600 | 0.97% | 20,000 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $840,000 | 0.96% | 80,000 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $816,600 | 0.93% | 30,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $762,600 | 0.87% | 30,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $750,000 | 0.86% | 30,000 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $348,480 | 0.40% | 12,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.